[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598689":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":160,"centralContacts":165,"locations":174,"responsibleParty":207,"collaborators":61,"id":209,"slug":210,"hasResults":211,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":61,"eligibilityCriteria":215,"healthyVolunteers":211,"sex":216,"minAge":217,"maxAge":61,"enrollmentInfo":218,"targetDuration":61,"studyType":221,"phases":222,"briefSummary":224,"conditions":225,"keywords":61,"overallStatus":177,"whyStopped":61,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,20,26],{"label":9,"type":10,"description":11,"interventionNames":12},"GHoST Master Protocol (remote chemotherapy management)","EXPERIMENTAL","Patients receive access to the remote chemotherapy management and patient monitoring platform to watch educational videos, report when medication is taken or missed, and report any symptoms related to cancer or medication side effects on study. Patients also receive standard of care chemotherapy as assigned by their treating physician as part of the platform on study. Upon completion of standard of care chemotherapy, if there is no disease progression, patients transition to surveillance for up to 1 year. Patients who experience disease progression during treatment or surveillance may rejoin the platform and\u002For be assigned by their treating physician to a different chemotherapy agent as part of the platform. Patients also undergo MRI or CT throughout the study.",[13,14,15,16,17,18,19],"Drug: Chemotherapy","Procedure: Computed Tomography","Other: Internet-Based Intervention","Procedure: Magnetic Resonance Imaging","Procedure: Neurologic Examination","Other: Questionnaire Administration","Behavioral: Surveillance",{"label":21,"type":10,"description":22,"interventionNames":23},"Subprotocol 1 Group A (propranolol, bevacizumab)","Patients receive propranolol PO BID and SOC bevacizumab IV every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.",[14,16,17,18,24,25],"Drug: Propranolol","Drug: Imipramine",{"label":27,"type":10,"description":28,"interventionNames":29},"Subprotocol 1 Group B (imipramine, bevacizumab)","Patients receive imipramine PO QD and SOC bevacizumab IV every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.",[14,16,17,18,25,30],"Drug: Bevacizumab",[32,41,57,62,82,92,95,102,108,114],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","Chemotherapy","Receive standard of care chemotherapy",[9],[38,39,40],"Chemo","Chemotherapy (NOS)","Chemotherapy, Cancer, General",{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"PROCEDURE","Computed Tomography","Undergo CT",[9,21,27],[47,48,49,50,51,52,53,54,55,56],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":6,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Internet-Based Intervention","Receive access to the remote chemotherapy management and patient monitoring platform",[9],null,{"type":42,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"Magnetic Resonance Imaging","Undergo MRI",[9,21,27],[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI",{"type":42,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"Neurologic Examination","Ancillary studies",[9,21,27],[87,88,89,90,91],"Nervous System Examination","Neurological Assessment","neurological exam","Neurological Examination","NVEXAM",{"type":6,"name":93,"description":84,"armGroupLabels":94,"otherNames":61},"Questionnaire Administration",[9,21,27],{"type":96,"name":97,"description":98,"armGroupLabels":99,"otherNames":100},"BEHAVIORAL","Surveillance","Undergo surveillance",[9],[101],"Epidemiology \u002F Surveillance",{"type":33,"name":103,"description":104,"armGroupLabels":105,"otherNames":106},"Propranolol","Given PO",[21],[107],"1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol, 525-66-6",{"type":33,"name":109,"description":104,"armGroupLabels":110,"otherNames":111},"Imipramine",[21,27],[112,113],"50-49-7","5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-",{"type":33,"name":115,"description":116,"armGroupLabels":117,"otherNames":118},"Bevacizumab","Given IV",[27],[119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159],"ABP 215","ABP-215","ABP215","Alymsys","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","Avegra","Avzivi","Aybintio","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Equidacent","CTP16","CT P16","CT-P16","FKB 238","FKB238","FKB-238","HD204","IBI 305","IBI-305","IBI305","Jobevne","Mvasi","Onbevzi","Oyavas","Vegzelma","Zirabev","SCT501","SIBP 04","SIBP-04","SIBP04","MB 02","MB-02","MB02",[161],{"name":162,"affiliation":163,"role":164},"Ugur T. Sener, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[166,171],{"name":167,"role":168,"phone":169,"phoneExt":61,"email":170},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":172,"role":168,"phone":173,"phoneExt":61,"email":61},"Cancer Center Clinical Trials","507-293-6386",[175,194],{"facility":176,"status":177,"city":178,"state":179,"zip":180,"country":181,"countryCode":182,"cosmosGeoPoint":183,"geoPoint":188,"contacts":189},"Mayo Clinic in Florida","RECRUITING","Jacksonville","Florida","32224-9980","United States","US",{"type":184,"coordinates":185},"Point",[186,187],-81.65565,30.33218,{"lat":187,"lon":186},[190,191,192],{"name":167,"role":168,"phone":169,"phoneExt":61,"email":170},{"name":172,"role":168,"phone":173,"phoneExt":61,"email":61},{"name":193,"role":164,"phone":61,"phoneExt":61,"email":61},"Wendy J. Sherman, MD",{"facility":163,"status":177,"city":195,"state":196,"zip":197,"country":181,"countryCode":182,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Rochester","Minnesota","55905",{"type":184,"coordinates":199},[200,201],-92.4699,44.02163,{"lat":201,"lon":200},[204,205,206],{"name":167,"role":168,"phone":169,"phoneExt":61,"email":170},{"name":172,"role":168,"phone":173,"phoneExt":61,"email":61},{"name":162,"role":164,"phone":61,"phoneExt":61,"email":61},{"type":208,"investigatorFullName":61,"investigatorTitle":61,"investigatorAffiliation":61,"oldNameTitle":61,"oldOrganization":61},"SPONSOR","100598689","a-digital-treatment-platform-for-the-delivery-of-home-based-sequential-therapy-in-patients-with-glioma-ghost-trial-100598689",false,"NCT07074756","A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial","MC240703 Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.\n\n  * NOTE: Patient may be enrolled following completion of surgery and\u002For radiation therapy for newly diagnosed or recurrent tumor.\n  * NOTE: Any number of prior recurrences is permitted\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60\n* Expected survival ≥ 6 months in the opinion of treatment team\n* Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations\n* Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only\n\n  * Exception: Not required if patient is already on treatment. May be obtained prior to next treatment as needed per clinical care\n* Provide written informed consent\n* Ability to complete assessments and questionnaires by themselves or with assistance\n* SUBSTUDY 1: Enrolled in GHoST Master Protocol per eligibility criteria of the master study and clinically appropriate to proceed with bevacizumab treatment at the discretion of the treating physician\n* SUBSTUDY 1: Diagnosis of recurrent glioblastoma and intention to treat with bevacizumab\n\n  * NOTE: Any number of prior recurrences is permitted\n  * NOTE: Prior limited use of bevacizumab for radiation necrosis\u002Ftreatment related edema is permitted. Prior use should not exceed four infusions with the last dose administered ≥ 4 weeks prior to enrollment in this substudy\n* SUBSTUDY 1: Willing and able to adhere to the substudy for the duration of the substudy including undergoing treatment, and attending scheduled visits, and examinations\n* SUBSTUDY 1: Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only\n* SUBSTUDY 1: Provide written informed consent\n* SUBSTUDY 1: Ability to complete assessments and questionnaires by themselves or with assistance\n\nExclusion Criteria:\n\n* Pregnant or nursing, imprisoned, or lacking capacity for understanding\n* Uncontrolled and\u002For intercurrent illness or other condition which limits safety of or compliance with study proceedings\n* SUBSTUDY 1: Pregnant or nursing, imprisoned, or lacking capacity for understanding\n* SUBSTUDY 1: Uncontrolled and\u002For intercurrent illness or other condition which limits safety of or compliance with study proceedings","ALL","18 Years",{"count":219,"type":220},202,"ESTIMATED","INTERVENTIONAL",[223],"NA","This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.",[226,227,228],"Glioma","Recurrent Glioma","Recurrent Glioblastoma","2026-08-06",{"date":231,"type":232},"2026-08-10","ACTUAL",{"date":234,"type":232},"2025-09-12",{"date":236,"type":220},"2028-08-31",{"name":5,"class":6},2]